MiR-338-3p Enhances Ovarian Cancer Cell Sensitivity to Cisplatin by Downregulating WNT2B

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Chemoresistance significantly impacts ovarian cancer patient outcomes.
• MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression and are often dysregulated in cancers.
• Understanding miRNA roles is crucial for developing novel cancer therapies.

Purpose of the Study:

• To investigate the function of miR-338-3p in cisplatin resistance in ovarian cancer.
• To elucidate the molecular mechanisms underlying miR-338-3p's role in chemoresistance.

Main Methods:

• Real-time quantitative PCR (RT-qPCR) to measure miR-338-3p and WNT2B expression.
• In vitro assays (MTT, transwell, flow cytometry) to assess cell proliferation, motility, and apoptosis.
• Western blot to analyze protein expression of WNT2B, EMT markers, and apoptosis regulators.
• Dual-luciferase reporter assay to confirm the targeting relationship between miR-338-3p and WNT2B.
• In vivo xenograft tumor model to evaluate the effect of miR-338-3p overexpression on tumor growth.

Main Results:

• miR-338-3p expression was significantly downregulated in cisplatin-resistant ovarian cancer tissues and cells.
• Overexpression of miR-338-3p increased ovarian cancer cell sensitivity to cisplatin.
• miR-338-3p inhibited proliferation, motility, and epithelial-mesenchymal transition (EMT), while promoting apoptosis by targeting WNT2B.
• In vivo studies confirmed that miR-338-3p overexpression enhanced cisplatin sensitivity and suppressed tumor growth.

Conclusions:

• miR-338-3p acts as a tumor suppressor in ovarian cancer.
• Restoring miR-338-3p levels can overcome cisplatin resistance by downregulating WNT2B.
• miR-338-3p represents a potential therapeutic target for improving ovarian cancer treatment outcomes.